期刊
NATURE REVIEWS MICROBIOLOGY
卷 12, 期 1, 页码 23-34出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrmicro3140
关键词
-
类别
资金
- US National Cancer Institute [R01 CA 139398]
- US National Institute of Health [T32 GM065841]
- US National Institute of General Medical Sciences
- NATIONAL CANCER INSTITUTE [R01CA139389, R15CA139398, P30CA015083] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065841] Funding Source: NIH RePORTER
Early-stage clinical trials of oncolytic virotherapy have reported the safety of several virus platforms, and viruses from three families have progressed to advanced efficacy trials. In addition, preclinical studies have established proof-of-principle for many new genetic engineering strategies. Thus, the virotherapy field now has available a diverse collection of viruses that are equipped to address unmet clinical needs owing to improved systemic administration, greater tumour specificity and enhanced oncolytic efficacy. The current key challenge for the field is to develop viruses that replicate with greater efficiency within tumours while achieving therapeutic synergy with currently available treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据